Late-life dementia has a strong heritable component. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The first SVD component accounted for 21.56%, 12.93%, 11.91% of the total co-variability between the pairs (cortical thickness, tau), (relative GM density, tau) and (absolute GM density, tau), respectively. 5 key findings →
Design: cross-sectional Participants: 222 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The genetic architecture of sporadic Early-Onset Alzheimer Disease (sEOAD, onset ≤65 years) remains largely unknown. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Progress in understanding the complexity of Alzheimer's disease informs the search for combination therapies that can successfully prevent or substantially slow the progression of the disease. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ε4 noncarriers and those with lower baseline amyloid burden. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the base-case analysis from the healthcare perspective, SoC was more clinically effective than BSC with a cost per QALY of $5211. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is the most widespread neurodegenerative disorder and a leading cause of dementia seen in clinical practice. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease (AD) is the most common form of dementia affecting more than 6 million people in the United States. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is a major health issue of global concern whereby there are minimal treatment options. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
Age-related hearing loss (ARHL) has emerged as a significant and potentially modifiable risk factor for neurodegenerative disorders, including Alzheimer's disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Sendai Framework for Disaster Risk Reduction 2015–2030 (SFDRR) is at its 10th anniversary amidst a rapidly changing climate, which, together with social vulnerabilities, have led to significant impacts on human health and well-being. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Statins show mixed results in CKD and ESRD, with limited benefits in reducing cardiovascular events in dialysis patients. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
41/100
Hepatocellular carcinoma (HCC) remains a major global health burden, ranking as one of the leading causes of cancer-related deaths worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is becoming a major public health problem in Sub-Saharan Africa (SSA), with prevalence increasing due to demographic transitions, increasing life expectancy, and increasing prevalence of non-communicable diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MobileNet achieved the highest overall performance, with an accuracy of 99.44%. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cardiovascular disease (CVD) and cancer remain the leading causes of mortality in the United States, where poor diet has surpassed smoking as the leading risk factor for death, and life expectancy has hit a plateau as CVD mortality has stagnated over the past decade. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review seeks to understand what urban planning and management can do to reduce disaster risk and help cities adapt to the impacts of climate change. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The origins of many diseases can be traced to the dynamic interplay of genetic predispositions and environmental exposures post-birth. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
is a heuristic that seeks to develop methodologies capable of identifying subtle behavior(s) that may flag emerging AD and other dementia related syndromes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →